[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565662":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":31,"locations":39,"responsibleParty":58,"collaborators":60,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":70,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":18,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":41,"whyStopped":18,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"University of Oslo","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Fasting group","EXPERIMENTAL","This group will fast 24 hours before and 24 hours after chemotherapy for all treatment cycles (4-6 cycles).",[13],"Other: Fasting",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","NO_INTERVENTION","This group will receive standard treatment, which include no fasting.",null,[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":18},"Fasting","Fasting implies 0 kilojoule. Water ad libitum is permitted.",[9],[25,29],{"name":26,"affiliation":27,"role":28},"Sonja Brunvoll, PhD","Department of Nutrition, University of Oslo","PRINCIPAL_INVESTIGATOR",{"name":30,"affiliation":27,"role":28},"Inger Ottestad, PhD",[32,36],{"name":26,"role":33,"phone":34,"phoneExt":18,"email":35},"CONTACT","+4792087911","s.h.brunvoll@medisin.uio.no",{"name":30,"role":33,"phone":37,"phoneExt":18,"email":38},"+4799735017","i.o.ottestad@medisin.uio.no",[40],{"facility":27,"status":41,"city":42,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Oslo","0372","Norway","NO",{"type":47,"coordinates":48},"Point",[49,50],10.74609,59.91273,{"lat":50,"lon":49},[53,55,56,57],{"name":54,"role":33,"phone":34,"phoneExt":18,"email":35},"Sonja H. Brunvoll, PhD",{"name":30,"role":33,"phone":37,"phoneExt":18,"email":38},{"name":54,"role":28,"phone":18,"phoneExt":18,"email":18},{"name":30,"role":28,"phone":18,"phoneExt":18,"email":18},{"type":28,"investigatorFullName":54,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Postdoctoral researcher Sonja H. Brunvoll, PhD (co-PI together with Inger Ottestad, PhD)",[61,63,65],{"name":62,"class":6},"Oslo University Hospital",{"name":64,"class":6},"St. Olavs Hospital",{"name":66,"class":67},"Akershus University Hospital Trust","UNKNOWN","100565662","feasibility-of-intermittent-fasting-during-chemotherapy-100565662",false,"NCT06645093","Feasibility of Intermittent Fasting During Chemotherapy","Intermittent Fasting During Curatively Intended Chemotherapy for Malignant Lymphoma - a Randomized Feasibility Trial","FasteStudien","Inclusion Criteria:\n\n* Patients diagnosed with diffuse large B-cell lymphoma planned to receive R-CHOP (rituximab, vincristine, doxorubicin, cyclophosphamide, and prednisolone) and Hodgkin lymphoma receiving ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine)\n* Age ≥ 18 years\n* ECOG status 0-2\n* Normal weight and overweight (BMI ≥ 18,5 kg\u002Fm\\^2)\n\nExclusion Criteria:\n\n* Receiving concurrent radiation therapy and\u002For treatment\n* Other concomitant disease that may make intermittent fasting complicated such as diabetes mellitus\n* ECOG status: \\> 3\n* BMI \\\u003C 18,5 kg\u002Fm2\n* Age \\> 80 years","ALL","18 Years","80 Years",{"count":80,"type":81},40,"ESTIMATED","INTERVENTIONAL",[84],"NA","The goal of this randomized controlled parallel group trial is to examine if fasting before and after chemotherapy is safe, feasible and acceptable. The study population will include patients with either Hodgkin lymphoma or Diffuse Large B Cell Lymphoma.\n\nThe main questions aimed to answer are:\n\nWhether fasting during chemotherapy is safe for patients, whether it is feasible to implement in a clinical setting, and whether patients find it acceptable.\n\nWe also want to examine a number of patient-reported outcome measures regarding health status and quality of life, such as dietary intake and adverse events from chemotherapy.\n\nResearchers will compare fasting to standard treatment.\n\nParticipants will:\n\n* Fast 24 hours before and 24 hours after chemotherapy in addition to standard treatment or receive only standard treatment\n* Keep a diary of their dietary intake 24 hours before and 24 hours after chemotherapy\n* Keep a diary of their dietary intake for three consecutive days between chemotherapy cycles\n* Answer questionnaires\u002Fquestions in relation to side effects from fasting, side effects\u002Fadverse events of chemotherapy, quality of life\n* Take bioimpedance analysis (including body mass index and body composition)\n* Take blood- and feces samples",[87,88,21],"Lymphoma","Cancer",[90,91,92,93,94,21],"Chemotherapeutic Toxicity","Chemotherapy","Adverse Effect","Short-term fasting","Feasibility studies","2026-08-18",{"date":97,"type":98},"2026-08-20","ACTUAL",{"date":100,"type":98},"2024-10-31",{"date":102,"type":81},"2026-12",{"name":5,"class":6},1]